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Abstract
Background: Although both circular RNAs (circRNAs) and autophagy are associated with the function of breast
cancer (BC), whether circRNAs regulate BC progression via autophagy remains unknown. In this study, we aim to
explore the regulatory mechanisms and the clinical significance of autophagy-associated circRNAs in BC.
Methods: Autophagy associated circRNAs were screened by circRNAs deep sequencing and validated by qRT-PCR
in BC tissues with high- and low- autophagic level. The biological function of autophagy associated circRNAs were
assessed by plate colony formation, cell viability, transwells, flow cytometry and orthotopic animal models. For
mechanistic study, RNA immunoprecipitation, circRNAs pull-down, Dual luciferase report assay, Western Blot,
Immunofluorescence and Immunohistochemical staining were performed.
Results: An autophagy associated circRNA circCDYL was elevated by 3.2 folds in BC tissues as compared with the
adjacent non-cancerous tissues, and circCDYL promoted autophagic level in BC cells via the miR-1275-ATG7/ULK1
axis; Moreover, circCDYL enhanced the malignant progression of BC cells in vitro and in vivo. Clinically, increased
circCDYL in the tumor tissues and serum of BC patients was associated with higher tumor burden, shorter survival
and poorer clinical response to therapy.
Conclusions: circCDYL promotes BC progression via the miR-1275-ATG7/ULK1-autophagic axis and circCDYL could
act as a potential prognostic and predictive molecule for breast cancer patients.
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Background
Breast cancer (BC) is the most common malignancy in
women worldwide [1]. Though BC patients have favor-
able prognosis due to recent advances in early diagnosis
and effective treatment, recurrence or metastasis
remained to threaten survival. Autophagy is a conserved
ubiquitous process and energy recycling system that de-
livers damaged organelles, misfolded proteins and
intracellular constituents to lysosomes for degradation
[2]. Dysregulation of autophagy causes various patho-
logical behaviors in eukaryotic cells and promotes pro-
gression of diseases [3], including cancer [4–6].
Autophagy provides energy for cancer cells in stress
condition (i.e. hypoxia, starvation) and helps sustain
their survival [7]. It has been reported that autophagy
promotes survival, proliferation, metastasis, and invasion
of BC cells via regulating autophagy associated genes
and non-coding RNAs [4, 8–12]. However, the under-
lying mechanisms, especially non-coding RNAs, in regu-
lating autophagy of BC progression are not yet fully
elucidated.
Circular RNAs (circRNAs) are a class of novel RNAs
with covalently closed loop structure without 5′ caps
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and 3′ tails [13]. Due to its loop structure, circRNAs are
resistant to exonuclease, so they are much more stable
than their parental linear RNAs and are abundant in
mammalian cells [14]. circRNAs display disease-specific
and development stage-specific characteristics under dif-
ferent pathologic environments [15–17], which suggests
that circRNAs can be used as potential biomarkers for
diagnosis and therapy [18, 19]. Several studies demon-
strated that circRNAs could act as miRNA sponges [7,
20–23], and circRNAs with intronic sequence could
regulate transcription of parental genes by interacting
with RNA polymerase II in the nucleus [24, 25], while
certain circRNAs exhibited the ability to translate pro-
teins [26–28].
The most frequently reported mechanism of circRNAs
is to trap miRNAs, known as miRNA sponge, leading to
functional loss of target miRNAs and subsequent upreg-
ulation of miRNA-targeted genes. circRNAs exhibit
powerful potential in regulating the biological functions
of BC cells, including proliferation, migration, invasion
[29–31]. Recently, some publications reported correla-
tions between circRNAs and autophagy in many diseases
such as thyroid cancer, myocardial ischemia/reperfusion
injury and sciatic nerve injury [10, 32, 33]. For example,
circ-Dnmt1 promoted the proliferation of BC cells via
autophagy by interfering with the nuclear localization of
p53 and AUF1 [10]. Nevertheless, the relationship be-
tween circRNAs and autophagy in breast cancer, as well
as the role of autophagy-associated circRNAs in clinical
diagnosis and treatment of breast cancer remain largely
illusive.
In this study, by using deep sequencing in BC tissues,
we identified an autophagy associated circRNA cir-
cCDYL, which was increased up to 3.2 folds in BC tis-
sues than that of adjacent non-cancerous tissues.
Although circCDYL is reported to be highly expressed
in hepatocellular carcinoma [34], bladder cancer [35]
and breast cancer [36], the functional role of circCDYL
in breast cancer still remains unknown. Herein, we
found that BC patients with higher circCDYL in the
serum or tumor tissues had shorter survival and poorer
clinical response to therapy. We further revealed that
circCDYL promoted autophagy level via sponging miR-
1275 and up-regulated the expression of autophagy-
associated gene ATG7 and ULK1. We demonstrated that
circCDYL promoted BC progression via autophagy both
in vitro and in vivo.
Material and methods
Patient samples and clinical database
In this study, three independent cohorts of BC patients
from Sun Yat-sen Memorial Hospital (SYSMH) were en-
rolled. Breast cancer patients (aged 32 to 81) without
any distant metastasis at first diagnosis between 1 June
2004 and 31 May 2018 were enrolled as Cohort 1 (n =
113). Paraffin-embedded BC tissue samples and paired
non-tumor tissue samples in Cohort 1 were collected for
in situ hybridization (ISH), immunohistochemical stain-
ing (IHC) or immunofluorescence (IF). In addition,
serum samples from two other cohorts of SYSMH were
collected for droplet digital PCR (ddPCR) detection (Co-
hort 2 was a retrospective cohort collected from 1
March 2017 to 30 September 2017, containing 14 benign
patients, 30 early breast cancer (EBC) patients and 18
metastatic breast cancer (MBC) patients; Cohort 3 was a
prospective cohort from 1 June 2015 to 1 April 2019, in
which only MBC patients at first diagnosis were en-
rolled). This work was approved by Sun Yat-sen Memor-
ial Hospital Ethics Committee (SYSY-KY-KS-2018-05).
Autophagosome detection in cell lines and paraffin-
embedded section of tissues
LC3 (MAP 1LC3B, Microtubule Associated Protein 1
Light Chain 3 Beta) is a recognized autophagic marker.
During the formation of autophagosomes, cytosolic LC3
(LC3-I) would be enzymatically cleaved and form
membrane-bound LC3 (LC3-II), which mainly locates in
autophagosomes. Therefore LC3-II is a hallmark for
autophagosome formation. In our study, mCherry-GFP-
LC3-labeled MDA-MB-231 was used to visualize autop-
hagosome and autolysosome. Since GFP is quenched in
autolysosome, green dots of unmerged pictures reflect
only autophagosomes, while red dots pictures reflect
both autophagosomes and autolysosomes. Therefore,
yellow and red dots of the merged picture reflect autop-
hagosomes and autolysosomes, respectively. For the im-
munofluorescence on paraffin-embedded sections of
human or animal tissue, the LC3 antibody were used to
detect the autophagosomes, which could be seen as LC3
dots. Autophagosomes of cell lines or tissue sections
were observed under confocal microscope in five ran-
dom fields and the average number of autophagic dots
in each cell were calculated to represent its autophagic
level.
circRNA pull-down
circRNA pull-down was performed using biotinylated
circCDYL probe, linear CDYL probe and negative con-
trol (NC) probe (Sangon Biotech, China) based on pro-
tocols from previous literatures [32, 37]. Briefly, MDA-
MB-231 was fixed with 1% formaldehyde for 30 mins
and lysed by co-IP buffer. The mixture was sonicated at
high amplitude for 30 cycles of 30 s (on/off) pulses. Then
the circCDYL-specific and NC biotinylated probes were
added to the supernatant and the mixtures were incu-
bated overnight at 37 °C. Next, the mixture was incu-
bated with C1 streptavidin magnetic beads for 30 min at
37 °C. Finally, total RNA in the solution was extracted
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followed by qRT-PCR detection of circCDYL, linear
CDYL RNA and miR-1275.
Dual luciferase reporter assay
Full-length sequence with wild-type or mutant sites of
circCDYL and linear CDYL were designed and inserted
into psiCHECK-2 vectors (Synbio-tech, Guangzhou,
China). psiCHECK-2 vectors carrying NC mimic or
miR-1275 mimic were co-transfected to HEK-293 T cells
respectively. After 48 h transfection, luciferase activity of
the transfected cells was detected by the dual-luciferase
reporter assay system (Vazyme, Nanjing, China).
In vivo breast cancer orthotopic model
The animal experiments were performed by Forevergen
Medical Corporation (Guangzhou, China), and all ex-
perimental procedures and animal care were in accord-
ance with the ethical guidelines of the institution. 4-
week-old female Balb/c nude mice were purchased from
Nanjing Biomedical Research Institute of Nanjing Uni-
versity (Nanjing, China). Luciferase-labeled MDA-MB-
231 cells (1X 106) transduced with sh-NC or sh-
circCDYL lentivirus (sh-circCDYL-1 or sh-circCDYL-2)
were directly injected into the fourth left mammary fat
pads of the nude mice (n = 6/group). The tumor size was
measured every 3 days by using Vernier caliper. When
the tumor volume of sh-NC group reached 1000mm3,
mice were given D-luciferin (300mg/kg; i.p.; 10 mins
prior to imaging), anaesthetized with 3% isoflurane and
imaged with a Xenogen IVIS Lumina system (Caliper
Life Sciences, Hopkinton, MA). The mice were then
sacrificed and the tumors were resected for IHC stain-
ing, ISH and IF.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 5 software. Student’s t-test or one-way ANOVA
was performed to test differences between groups in
both in vivo and in vitro experiments. X2-test was ap-
plied to analyze the correlations between circCDYL ex-
pression and clinicopathological characterization of BC
patients. Kaplan-Meier plots and Log-rank tests were
used for survival analysis. The univariate analyses were
analyzed by Cox proportional hazards model. The corre-
lations were analyzed using Pearson’s correlation coeffi-
cients. P < 0.05 was considered statistically significant.
Additional material and methods
Additional materials and methods can be found in Sup-
plementary Information.
Results
Identification of autophagy-associated circRNAs in breast
cancer
In order to determine the clinical significance of autoph-
agy in breast cancer, the expression of LC3 detected by
IHC in breast cancer patients was analyzed in Cohort 1.
The median value of LC3 level was used as a cut-off
value to divide these patients into LC3High and LC3Low
subgroups. Survival analysis revealed that patients in
LC3High subgroup had a poorer disease-free survival
(DFS) than LC3Low subgroup (HR 2.069, 95% CI 1.059–
4.044, P = 0.033, Fig. S1A). However, IHC staining on
tumor section only reflected the total protein expression
level of LC3, but not LC3-II (An acknowledged hallmark
of autophagosome). Therefore, detecting LC3 dots by
immunofluorescence (IF) was visible and allowed us to
calculate autophagosomes. The median number of LC3
dots was used as a cut-off value to divide Cohort 1 into
LC3-dotsMore and LC3-dotsLess subgroups. Survival ana-
lysis showed that LC3-dotsMore subgroup had a poorer
DFS (HR 3.095, 95% CI 1.577–6.073, P = 0.01, Fig. 1a).
These results indicated that autophagy plays an import-
ant role in breast cancer progression.
To further screen autophagy-associated circRNAs in
breast cancer, circRNAs deep sequencing was performed
to compare the difference of circRNAs profiles in pri-
mary BC tissues with more (LC3-dotsMore, n = 5) and
less (LC3-dotsLess, n = 5) LC3 dots (Fig. 1b). 38 circRNAs
candidates were selected based on the following stan-
dards: (i) fold change > 2; (ii) Junction reads per million
mapped reads (RPM) > 200 (Table S1). From these can-
didates, we further narrow down the selection by select-
ing top ten circRNAs. Then we performed qRT-PCR to
further quantify this result in LC3-dotsMore (n = 23) and
LC3-dotsLess BC tissues (n = 22), and found that only
three circRNA candidates - hsa_circ_0008285 (derived
from CDYL gene, hereafter termed as circCDYL), hsa_
circ_0024604 and hsa_circ_0007059 were consistent
with the result of circRNAs deep sequencing (Fig. 1c,
Fig. S1B). Next, we established two autophagy induction
breast cancer cell models in vitro under hypoxia and
EBSS starvation treatment (Fig. S2A-2C), and found that
only circCDYL was up-regulated in both models (Fig.
1d, Fig. S2D-E). All these data above indicated that cir-
cCDYL is an autophagy associated circRNA, and the
basic characteristic of circCDYL has been reported in
published research [34].
High circCDYL is associated with poor prognosis and
clinical response in BC patients
The expression of circCDYL and linear CDYL in 113 BC
tissues and 47 corresponding paired non-cancerous tis-
sues from Cohort 1 were detected by ISH. circCDYL
and linear CDYL was elevated up to 3.2 and 1.5 folds
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respectively in BC tissues than adjacent non-cancerous
tissues (Fig. 2a, Fig. S3A). The clinicopathological fea-
tures were analyzed based on expression of circCDYL or
linear CDYL in BC tissues (Table 1, Table S2). Higher
circCDYL expression was significantly associated with
ER negative status, higher Ki67 index, larger tumor size
and more lymphatic metastasis. No correction was found
between linear CDYL and these clinicopathological fea-
tures. In addition, the Pearson correlation analysis
showed that circCDYL and linear CDYL expression was
positively correlated with the number of LC3 dots (cir-
cCDYL: r = 0.712, linear CDYL: r = 0.298) (Fig. 2b, Fig.
S3B). The expression of circCDYL and linear CDYL was
increased up to 2.2 and 1.2 folds in LC3-dotsMore tissues,
when comparing with LC3-dotsLess tissues (Fig. 2c, Fig.
S3C). A Kaplan-Meier analysis indicated that patients
with high circCDYL had a poorer disease-free survival
(DFS) (HR 2.85, 95% CI 1.415–5.739, P = 0.0036, Fig.
2d), but expression of linear CDYL had no effect on DFS
of BC patients (Fig. S3D). These results suggested that
circCDYL may play more important role in breast can-
cer than linear CDYL.
Next, BC patients’ serum from Cohort 2 and Cohort 3
were collected. Droplet digital PCR (ddPCR) were per-
formed to verify the abundance of circCDYL in serum of
these patients. Clinical data from Cohort 2 showed that
circCDYL was the most abundant in the serum from
metastatic breast cancer (MBC) patients, compared to
early breast cancer (EBC) and benign patients (Fig. 2e).
We further detected the real time kinetics of serum cir-
cCDYL in MBC patients (n = 18) during chemotherapy
and found that reduction of circCDYL is positively cor-
related to a better sensitivity to clinical therapy (Fig. 2f).
In addition, survival analysis from Cohort 3 containing
Fig. 1 Autophagy-associated circRNA (circCDYL) expression profile in breast cancer. a The association between LC3 dots and disease-free survival
(DFS) in 113 breast cancer patients from Cohort 1 of SYSMH. b circRNA expression profile in breast cancer patients with more and less LC3 dots
by circRNA deep sequencing. c Expression of circCDYL in breast cancer tissue with more (n = 23) and less (n = 22) LC3 dots by qRT-PCR. d The
relative expression of circCDYL under hypoxic condition (0.2% O2) at various time points (0, 24, 48 h) (left) and EBSS starvation induction at
various time points (0, 2, 4, 6 h) (right) in MDA-MB-231 cells
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30 MBC patients showed that patients with high serum
circCDYL had a poorer overall survival (HR 3.748, 95%
CI 1.233–11.239, P = 0.002, Fig. 2g). These clinical data
suggested that circCDYL may be a potential molecule
for predicting the prognosis and therapy response of BC
patients.
circCDYL regulates the proliferation of BC cells via
autophagy
To investigate the biological function of circCDYL, the ex-
pression of circCDYL was downregulated by RNAi-
mediated gene silencing using siRNA (Fig. S4A) and lenti-
shRNA (Fig. S4B). Overexpression of circCDYL was car-
ried out through transfection of circCDYL over-
expressing plasmids (Fig. S4C) or circCDYL over-
expressing lentivirus (Fig. S4D) without influencing the
expression of linear CDYL RNA. Next, we found that in-
hibition of autophagy by bafilomycin A1 (Baf A1, an au-
tophagy inhibitor) had no influence on the expression
level of circCDYL in MDA-MB-231 cells (Fig. 3a, Fig.
S4E). However, silencing or over-expression of circCDYL
resulted in down- or up- regulation of the basal autopha-
gic level of MDA-MB-231 cells as determined by LC3-II
protein level (Fig. 3b). To visualize autophagosomes, we
then established a stable MDA-MB-231 cell line with LC3
labeled by mCherry and GFP. LC3 dots were increased
after circCDYL overexpression in LC3-mCherry-GFP-la-
beled MDA-MB-231 cells, and decreased after circCDYL
silencing (Fig. 3c, Fig. S4F). All these indicate that cir-
cCDYL affects autophagic level in BC cells, but autophagy
did not affect the expression of circCDYL.
Next, we investigated the biological function of cir-
cCDYL in BC cells. Cell viability assays indicated that the
proportion of living cells were increased after circCDYL
overexpression, and significantly decreased after siRNA si-
lencing of circCDYL in both MCF-7 and MDA-MB-231
(Fig. 3d). Similarly, plate colony formation assay showed
that colony formation increased after circCDYL overex-
pression and decreased after circCDYL silencing (Fig. 3e,
Fig. S4G). However, circCDYL expression level had no sig-
nificant effect on the invasion and apoptosis in MDA-MB-
231 cells (Fig. S4H-I). Both plate colony formation assay
and cell viability assay showed that inhibition of
(See figure on previous page.)
Fig. 2 Clinical significance of circCDYL in breast cancer. a Comparison of circCDYL expression between breast cancer tissues and paired adjacent
non-cancerous tissues by qRT-PCR (n = 47) and their representative images by ISH. Scale bar = 50 μm. b Correlations of circCDYL expression and
the number of LC3 dots in breast cancer tumors, analyzed by Pearson analysis. c Representative images of LC3 dots and circCDYL expression by
ISH in breast cancer tissues (left) and quantitative analysis of circCDYL expression in cancer tissues with more and less LC3 dots. Scale bar =
50 μm. d Kaplan-Meier analysis of the correlation between circCDYL expression and disease-free survival (DFS). e circCDYL abundance in serum of
patients detected by ddPCR (n = 62, Cohort 2). EBC: early breast cancer, MBC: metastatic breast cancer. f Representative images in cases with lung
and liver metastasis before and after chemotherapy and real time kinetics of serum circCDYL during chemotherapy in MBC patients (n = 18,
Cohort 2). PR: partial response; CR: complete response; PD: progressive disease; SD: stable disease. g Kaplan-Meier analysis of the correlation between
serum circCDYL expression and overall survival (OS) in MBC patients (Cohort 3). *P < 0.05, **P < 0.01, ***P < 0.005. Error bars indicate Standard
Error of Mean (S.E.M)
Table 1 Patient characteristics stratified by circCDYL expression
Number of patients Total P value
Low circCDYL High circCDYL
Age 0.728
>35 50 52 102
≤ 35 6 5 11
Menopause 0.644
Yes 35 38 73
No 21 19 40
ER status 0.035
Negative 14 25 39
Positive 42 32 74
PR status 0.106
Negative 30 39 69
Positive 26 18 44
HER2 status 0.20
Negative 38 32 70
Positive 18 25 43
Ki67 Level < 0.0001
Low 48 20 68
High 8 37 45
Molecular subtype 0.102
Luminal 42 32 74
HER2+ 7 11 18
TNBC 7 14 21
Tumor stage 0.001
T1 27 11 38
T2 23 28 51
T3–4 6 18 24
Lymphatic stage 0.046
N0 28 17 45
N1 16 17 33
N2–3 12 23 35
Abbreviations: ER estrogen receptor, PR progesterone receptor, HER2 human
epidermal growth receptor 2
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autophagic flux by Bafilomycin A1 attenuated the effect of
circCDYL overexpression on proliferation in MDA-MB-
231 and MCF-7 cell lines (Fig. 3f-g, Fig. S4J).
In addition, we designed three siRNAs: (i) target
against circCDYL only (si-circ), (ii) target against linear
CDYL only (si-linear), and (iii) target against both cir-
cCDYL and linear CDYL (si-cl) (Fig. S5A). Both si-circ
and si-cl transfection had similar effect on the decreased
proliferation of MDA-MB-231 and MCF-7 cells, while
si-linear transfection had no significant effect on cell
proliferation (Fig. S5B). In addition, both si-circular and
si-cl transfection increase autophagic level by detecting
protein level of LC3-II, while si-linear showed little effect
on autophagy regulation (Fig. S5C). The result above in-
dicates that circCDYL but not linear CDYL has the bio-
logical function on proliferation and autophagy
regulation.
circCDYL works as miR-1275 sponge in breast cancer cells
It has been demonstrated that circRNAs have a potential
to work as a miRNA sponge if the circRNAs can form a
circRNA-AGO2-miRNA complex by binding to AGO2
and miRNAs [22, 23, 38]. AGO2 RIP assay confirmed
that AGO2 could bind circCDYL (power value =
10.7*10− 9, Fig. 4a), suggesting that circCDYL may work
as a miRNA sponge. We successfully established cir-
cRNAs pull-down assay using biotinylated probes specif-
ically against circCDYL (Fig. S6A). We purified the
circCDYL-binding RNAs by circRNAs pull-down and
scanned the candidate miRNAs by miRNAs microarray
(Fig. 4b, Table S3). We selected the miRNA candidates
that met the following criteria: (i) fold change > 3 com-
pared to NC; and (ii) normalized intensity of miRNA
candidates > 100. miR-1275 was the only specific spon-
ging miRNA for circCDYL (Fig. 4b). We then verified
the results of miRNA microarray by qRT-PCR and
found that miR-1275 was enriched by circCDYL probe
(Fig. 4c). Similarly, miRNA pull-down assay showed that
biotinylated miR-1275 also enriched circCDYL (Fig. 4d).
In addition, we tested the basic expression of miR-1275
as well as other miRNAs that were known to be highly
upregulated in breast cancer (including miR-7, miR-30c,
miR-135b, miR-16, miR-206, miR-200a) [39, 40]. Expres-
sion of miR-1275 was similar to miR-30c, miR-135b and
miR-7, and significantly higher than miR-200a and miR-
206 in MDA-MB-231 cells (Fig. S6B). Further analysis
from online website RNAhybrid 2.0 (https://bibiserv.
cebitec.uni-bielefeld.de/rnahybrid/) showed that cir-
cCDYL had 3 binding sites of miR-1275 (Fig. S6C). To
further confirm this result, we performed a dual lucifer-
ase reporter assay by co-transfecting miR-1275 mimic
and the luciferase reporters into HEK-293 T cells. In the
non-mutant groups, miR-1275 mimic reduced the lucif-
erase reporter activity by 65%, and this result can be re-
versed after mutating either binding site 2 or 3 of
circCDYL sequence in luciferase reporters, indicating
that circCDYL bound to miR-1275 specifically at these
two binding sites (Fig. 4e). In addition, the expression of
miR-1275 remained unchanged after silencing of cir-
cCDYL in both MCF-7 and MDA-MB-231 cells, sug-
gesting that circCDYL interacted with miR-1275 without
affecting the expression of miR-1275 (Fig. S6D). In LC3-
mCherry-GFP-labeled MDA-MB-231 cell, LC3 dots
were increased after miR-1275 inhibitor transfection and
significantly decreased after miR-1275 mimic transfec-
tion, suggesting miR-1275 promoted autophagic level
(Fig. 4f, Fig. S6E). In MDA-MB-231 cells, LC3-II was
up-regulated after miR-1275 inhibitor transfection and
down-regulated after miR-1275 mimic transfection (Fig.
4g). Cell viability assays indicated that the proliferative
speed was faster after miR-1275 inhibitor transfection
and was slower after miR-1275 mimic treatment in both
MCF-7 and MDA-MB-231 (Fig. S6F).
circCDYL promotes autophagic flux via miR-1275 and is
responsible for the proliferation of BC cells
We then tested whether circCDYL regulated autophagic
level and proliferation via miR-1275 sponging mechan-
ism. In MDA-MB-231 cells, Western Blot indicated that
co-transfection with miR-1275 mimic and circCDYL
over-expressing plasmid could restore the effect of LC3-
II up-regulation by circCDYL overexpression, in con-
trast, co-transfection with miR-1275 inhibitor and cir-
cCDYL siRNA could restore the effect of LC3-II down-
regulation via circCDYL silencing (Fig. 4h). In addition,
in mCherry-GFP-LC3-labeled MDA-MB-231, we ob-
served that co-transfection of miR-1275 mimic and cir-
cCDYL over-expressing plasmid partially restored the
(See figure on previous page.)
Fig. 3 circCDYL promotes proliferation of breast cancer cells via autophagy. a qRT-PCR analysis of circCDYL in MDA-MB-231 cells after Baf A1
(Bafilomycin A1) treatment. b LC3 expression in MDA-MB-231 after circCDYL silencing via siRNA or over-expressing circCDYL by over-expressing
plasmid, as detected by Western Blot. LC3-II/I, the gray value ratio of LC3-II and LC3-I, normalized to NC group. c Autophagosomes in mCherry-
GFP-LC3 labeled MDA-MB-231 after silencing circCDYL via siRNA or over-expressing circCDYL by over-expressing plasmid, as detected by confocal
microscopy. Scale bar = 50 μm. d, e The proliferation of MDA-MB-231 and MCF-7 cells after silencing circCDYL viasiRNA or over-expressing
circCDYL via over-expressing plasmid, as detected by cell viability assay (d) and plate colony formation (e). f, g Proliferation of MDA-MB-231 and
MCF-7, as detected by plate colony formation (f) and cell viability assay (g) after transfection with circCDYL over-expressing plasmid or co-
treatment with Baf A1. siNC: negative control siRNA. All experiments above were repeated at least 5 times. *P < 0.05, **P < 0.01, ***P < 0.005. Error
bars indicate S.E.M
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effect of circCDYL overexpression on the increased au-
tophagic level, while co-transfection of miR-1275 inhibi-
tor and circCDYL siRNA partially rescued this effect of
circCDYL silencing (Fig. S6G). In addition, plate colony
formation assay and cell viability assay showed that
transfection of miR-1275 mimic also partially restored
the proliferation-promoting effect after circCDYL over-
expression in both MCF-7 and MDA-MB-231 cells,
while addition of miR-1275 inhibitor partially rescued
the effect of knocking down circCDYL (Fig. 4i-j).
circCDYL regulates ATG7 and ULK1 expression via miR-
1275 sponge
Three online websites, TargetScanHuman, miRNA.org
and miRNAWalk, were used to predict the potential tar-
get genes of miR-1275. As shown in Fig. S7A, total seven
autophagy-associated genes, including ULK1, ATG3,
ATG4C, ATG4D, ATG7, ATG10, ATG14, were shown
as the target genes of miR-1275 in at least two online
websites. We further confirmed that miR-1275 mimic
decreased ULK1 and ATG7 expression at RNA level by
55 and 63% respectively, while miR-1275 inhibitor in-
creased ULK1 and ATG7 expression by 83 and 180% in
MDA-MB-231 (Fig. 5a). However, ectopic expression of
miR-1275 has no influence on the expression of ATG3,
ATG4C, ATG4D, ATG10 and ATG14 (Fig. S7B). West-
ern Blot analysis indicated that miR-1275 mimic de-
creased the protein level of ULK1 and ATG7, while
miR-1275 inhibitor increased these proteins in MDA-
MB-231 (Fig. 5b). Furthermore, miR-1275 pull-down
assay showed that biotinylated miR-1275 mimic enriched
ATG7 and ULK1 mRNA, suggesting that ATG7 and
ULK1 are the target genes of miR-1275 (Fig. S7C).
Moreover, we found that overexpressing circCDYL-wt
significantly increased ATG7 and ULK1 expression,
while the circCDYL-mu overexpressing had no effect on
ATG7 and ULK1 regulation (Fig. S7D). Transfection of
miR-1275 inhibitor could restore ATG7 and ULK1 ex-
pression after circCDYL knockdown, and transfection of
miR-1275 mimic could restore ATG7 and ULK1 expres-
sion after circCDYL overexpression at both RNA and
protein level (Fig. 5c, d). The results above indicate that
circCDYL regulates the expression of ATG7 and ULK1
via miR-1275 sponge.
Next, we elucidated whether circCDYL regulates au-
tophagy and proliferation of breast cancer cells via miR-
1275-ATG7/ULK1 axis. By using siRNA, we successfully
silenced ATG7 or ULK1 in both MCF-7 and MDA-MB-
231 cells (Fig. S7E). Importantly, silencing of ATG7 or
ULK1 restored the effect of circCDYL overexpression on
increasing the autophagic marker LC3-II, as detected by
Western Blot (Fig. 5e). In addition, silencing ATG7 re-
stored the inhibitory effect of circCDYL overexpression
on increasing autophagosomes in mCherry-GFP-labeled
MDA-MB-231 cells, as determined by LC3 dots (Fig.
S7F). In functional experiments, plate colony formation
assay showed that the proliferation-promoting effect of
circCDYL overexpression was attenuated after co-
transfection of circCDYL overexpression plasmid with
ATG7 or ULK1 siRNA (Fig. 5f).
In addition, we tested the Ki67, ATG7 and ULK1 by
IHC, LC3 dots by IF and circCDYL expression by ISH in
tumor tissues of Cohort 1 (Fig. S8A). The tumor tissues
with higher CDYL expression exhibited a higher Ki67
index (Fig. S8B). Linear regression analysis showed the cir-
cCDYL expression was positively associated with ATG7
and ULK1 expression (Fig. S8C). Low ATG7 or ULK1 was
associated with longer DFS among these patients (ULK1:
HR 2.745, 95% CI 1.393-4.410, P = 0.0037; ATG7: HR
1.98, 95% CI 1.012–3.909, P = 0.0462, Fig. S8D).
Linear CDYL has weak potential to act as miR-1275
sponge
We then examined whether circCDYL possesses more
miR-1275 sponging power compared to linear CDYL via a
series of experiments. Firstly, AGO2 RIP assays were
employed and showed that AGO2 antibody enriched much
more circCDYL than linear CDYL (circCDYL: power value
=10.7*10− 9; linear CDYL: power value =2.2*10− 9) (Fig. 4a,
Fig. S9A). Secondly, two luciferase reporter plasmids with
total length of linear CDYL or circCDYL were conducted.
Luciferase reporter assays showed that overexpression of
miR-1275 mimic dramatically reduced the circCDYL lucif-
erase reporter activity up to 65% but only reduced linear
CDYL luciferase reporter activity by 25% (Fig. 4e and Fig.
(See figure on previous page.)
Fig. 4 circCDYL functions as miR-1275 sponge. a qRT-PCR analysis of circCDYL in RNA sample after RIP assay by AGO2 antibody. b Heatmap of
miRNA microarray of RNA sample by circCDYL pull-down. c qRT-PCR analysis of miR-1275 in RNA sample by circCDYL pull-down. d qRT-PCR
analysis of circCDYL in RNA sample by miR-1275 miRNA pull-down. e Dual luciferase assay of HEK-293 T cells co-transfected with miR-1275 mimic
and luciferase reporter containing full length of circCDYL with or without miR-1275 binding site mutant. NC: negative control; WT: wild-type
luciferase reporter containing full length of circCDYL. f LC3 dots in mCherry-GFP-LC3-labeled MDA-MB-231 cells. g LC3-II expression in MDA-MB-231
after treatments with miR-1275 mimic or inhibitor, as detected by Western Blot. h Western Blot analysis of LC3-II expression in MDA-231 co-
transfected with circCDYL over-expressing plasmid and miR-1275 mimic or co-transfected with circCDYL specific siRNA and miR-1275 inhibitor. i-j.
Proliferation level of MCF-7 and MDA-MB-231 detected by cell viability assay (i) and plate colony formation (j) after co-transfection with circCDYL
over-expressing plasmid and miR-1275 mimic or co-transfection with circCDYL specific siRNA and miR-1275 inhibitor. All data are shown as the
mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.005
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Fig. 5 circCDYL promotes proliferation of breast cancer cells via miR-1275-ATG7/ ULK1-autophagic axis. a ATG7 and ULK1 expression of MDA-MB-
231 after transfection with miR-1275 mimic or inhibitor, as detected by qRT-PCR. b ATG7 and ULK1 expression of MDA-MB-231 after transfection
with miR-1275 mimic or inhibitor, as detected by Western Blot. c, d ATG7 and ULK1 expression in MDA-MB-231 after transfection with circCDYL
over-expressing plasmid and ATG7 or ULK1 siRNA, as detected by qRT-PCR (C) and Western Blot (D). e Western Blot analysis of LC3-II expression
in MDA-MB-231 after co-transfection with circCDYL over-expressing plasmids and ATG7 or ULK1 siRNA. f Proliferation level of MCF-7 and MDA-
MB-231 after co-transfection with circCDYL over-expressing plasmids and ATG7 or ULK1 siRNA, as detected by plate colony formation
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Fig. 6 circCDYL promotes progression of breast cancer in vivo. a Tumor size derived from MDA-MB-231 cell line was measured in Balb/c nude
mice with orthotopic tumors in the fourth left mammary fat pad. b Live imaging of the animals prior to euthanasia, and photon intensities are
indicated above the picture. c, d Tumor size (C) and tumor weight (D) measured after tumor excision. e IHC staining of ATG7, ULK1 and Ki67, and
IF detection of LC3 dots in orthotopic tumors derived from MDA-MB-231 cell line. Scale bar = 50 μm
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S9B). Furthermore, circCDYL pull-down and linear CDYL
pull-down assay revealed that, compared with linear CDYL
probes, circCDYL probe enriched much more miR-1275
(circCDYL probes: power value =5.9*10− 10; linear CDYL
probes: power value =1.4*10− 11) (Fig. 4c and Fig. S9C).
Moreover, the inhibitory effect of miR-1275 mimic on
ATG7 and ULK1 expression could be only rescued by over-
expressing circCDYL but not by linear CDYL overexpres-
sion in the MDA-MB-231 cells (Fig. S9D). Therefore, the
results above provides further evidence that circCDYL pos-
sesses more miR-1275 sponging power compared to linear
CDYL.
circCDYL promotes proliferation via autophagy in breast
cancer orthotopic animal model
To further confirm that circCDYL could promote BC
cells proliferation in vivo, we established breast cancer
orthotopic model in Balb/c nude mice. The tumors de-
rived from MDA-MB-231 cells with stable knockdown
of circCDYL (sh-circCDYL) had significantly slower
growth than the control group (sh-NC) (Fig. 6a). The
average tumor size of sh-circCDYL group was much
smaller than sh-NC group as indicated by live imaging
(Fig. 6b) or by measuring tumor sizes after tumor exci-
sion (Fig. 6c). sh-circCDYL group had a lighter weight
than sh-NC group (Fig. 6d). In addition, the resected tu-
mors were made into paraffin-embedded sections,
followed by detection of ATG7, ULK1, LC3 dots and
Ki67. sh-circCDYL group had lower expression of
ATG7, ULK1, less LC3 dots and lower Ki67 index than
sh-NC group (Fig. 6e). The results demonstrate that cir-
cCDYL plays an important role in promoting breast can-
cer progression in vivo via autophagy.
Discussion
Breast cancer is the most common malignancies among
women [1, 41]. Though breast cancer exhibits good
prognosis, some breast cancer patients still suffer tumor
progression. One of the emerging concepts to promote
progression of breast cancer is autophagy [4, 8–11]. It is
now known that the dysregulation of autophagy pro-
motes progression of breast cancer. However, the mo-
lecular mechanism of autophagy in the progression of
breast cancer is still unknown. In this study, we identi-
fied and characterized an autophagy associated circRNA
circCDYL by deep sequencing in BC tissues with differ-
ent autophagic level. Clinically, data from three inde-
pendent cohorts showed the strong clinical relevance
between circCDYL expression and prognosis as well as
clinical response to therapy in breast cancer patients.
Mechanistically, circCDYL accelerates autophagic flux
via sponging miR-1275 and affects its downstream tar-
geted gene ATG7 and ULK1, thus promotes the prolifer-
ation of breast cancer (Fig. S10). It is well known that
ULK1 is key molecule in ULK1 complex, which is essen-
tial in the initiation of autophagy [42]. ATG7 acts as an
E1-like activating enzyme to transform LC3-I to LC3-II by
conjugation of LC3-I with phosphatidylethanolamine (PE)
during autophagosome formation, and LC3-II plays an es-
sential role in autophagosome formation [43]. All these
suggest that circular circCDYL promotes proliferation of
breast cancer via escalation of autophagic flux and plays
an important role in the progression of breast cancer.
circRNAs are generally considered to be molecular
flukes or byproducts of transcription. However, increas-
ing evidences indicate that circRNAs are abundant in
cells and play an important role in regulating disease
progression [30]. Tantamount studies indicate that cir-
cRNAs work as miRNA sponge by trapping and halting
the function of target miRNAs [7, 20–22]. Various stud-
ies indicate that circRNAs with intronic sequence may
regulate transcription of parent genes in the nucleus [24,
25] and circRNAs with internal ribosome entry site
(IREs) and open reading frame (ORF) could potentially
be translated into proteins [26–28]. circCDYL, a circular
RNA derived from the fourth exon of CDYL gene, is
mainly located in cytoplasm and had no intronic se-
quence, IREs and ORF (online website: http://reprod.
njmu.edu.cn/circrnadb, data not shown), suggesting that
circCDYL might not locate in nucleus or translate into
proteins. Emerging evidences shows that certain cir-
cRNAs can form a circRNAs-miRNA-AGO2 complex if
the circRNA can work as miRNA sponge [22, 23, 38].
According to our data, AGO2 RIP experiment shows
that circCDYL indeed bind to AGO2, confirming cir-
cCDYL’s role as a miRNA sponge. We used circRNAs
pulldown experiments and miRNA microarray to verify
the miRNA candidate of circCDYL. miRNAs pulldown
and circRNA pulldown as well as dual-luciferase re-
porter assay demonstrated that circCDYL functions as
miR-1275 sponge and has two binding sites for miR-
1275. In addition to the discovery of circCDYL, to the
best of our knowledge, this is the first report in elucidat-
ing the role of miR-1275 in breast cancer, and we are
the first to prove that miR-1275 inhibits proliferation of
breast cancer cells.
It is interesting that only circCDYL has the biological
function on proliferation and autophagy regulation,
while the linear form of CDYL do not possess the same
function., although they have the same miR-1275 biding
sites. Several reasons may account for this: (i) Our re-
search indicates that miR-1275 sponge potential of cir-
cCDYL is much stronger than linear CDYL. (ii) The
major function of linear CDYL is to work as mRNA and
translate into protein, and CDYL protein may play dif-
ferent role in biological function. The mechanism func-
tion of linear CDYL is much more complex than
circCDYL, and further researches are required.
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Identifying new molecular biomarkers for diagnosis
and predicting prognosis and clinical efficacy of breast
cancer patients is of high clinical significance. In this
current study, we found that circCDYL expression in
both breast cancer patients’ serum and tissue were much
more abundant than those from the normal donors and
adjacent normal tissues, suggesting that circCDYL could
be utilized as a molecule for breast cancer diagnosis and
therapy. Second, clinical data showed that increased cir-
cCDYL in breast cancer tissues was associated with
more advance clinical stage, more metastasis and shorter
survival, indicating that circCDYL could be a potential
molecule for predicting breast cancer prognosis. Besides,
the expression level of circCDYL in breast cancer tissues
was positively associated with the level of LC3 dots, indi-
cating that circCDYL could be a marker reflecting au-
tophagic level of cancer.
Interestingly, we observed a real time kinetics of serum
circCDYL in MBC patients and found that serum cir-
cCDYL level was decreased in patients who responded
well to chemotherapy, indicating that serum circCDYL
level might be a potential molecule to predict the clinical
response to anti-cancer therapy. Several hypotheses are
proposed to address this clinical relevance. (i) The abun-
dance of circCDYL in cancer tissue were released into
circulation as necrosis occurs due to ischemic and hyp-
oxic tumor microenvironment, which could lead the in-
duction of autophagy. We found that circCDYL
expression was significantly increased in BC cells after
hypoxia or starvation treatment, suggesting that more
circCDYL were released into circulation when tumor
cells are in hypoxic or ischemic condition. (ii) Circulat-
ing tumor cells (CTCs) bring circCDYL into the circula-
tion, which could be a reservoir for circCDYL molecules.
MBC patients are reported to have more CTCs [44] and
our study found that MBC patients had more serum cir-
cCDYL than EBC patients, indirectly validating this hy-
pothesis. (iii) Breast cancer cells release circCDYL
through exosomes secretion. One research indicated that
lung cancer cells can secret exosomal circCDYL and re-
lease into circulation [45], indicating that this pathway
might be true for breast cancer as well. Furthermore,
confirming the expression of circRNA biomarkers by
minimally invasive liquid biopsies allows the clinician to
monitor breast cancer progression and response to treat-
ment in real-time setting, which would significantly im-
prove the development of earlier intervention and to
develop more precise therapy strategies that tailors to in-
dividual needs.
Conclusion
In summary, we identified an autophagy-associated cir-
cRNA (circCDYL) and demonstrated its strong correla-
tions with autophagy in breast cancer, as well as its
prognostic and predictive value in breast cancer patients.
Mechanistically, we proved that circCDYL regulates pro-
liferation of breast cancer cells via miR-1275-ATG7/
ULK1-autophagic axis. circCDYL could be used as a
novel circRNA biomarker for predicting the prognosis
and clinical response to therapy as well as a potential
therapeutic target, which provide real-time information
for decisions making in personalized treatments.
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